The chart below summarizes recommendations regarding screening for sexually transmitted infections from three organizations: the American Congress of Obstetricians and Gynecologists (ACOG), the U.S. Preventive Services Task Force (USPSTF), and the Centers for Disease Control and Prevention (CDC).

[tabby title=”Chlamydia”]

American Congress of Obstetricians and Gynecologists (ACOG)

  • Annual Screening for sexually active females age 25 and younger
  • Screening for women over age 25 with risk factors (e.g., new/multiple partners)

U.S. Preventive Services Task Force (USPSTF)

  • Screening for all sexually active non-pregnant females age 24 and younger. The optimal interval for screening this population is not known; noted that CDC recommends annually.
  • Screening for all pregnant women ages 24 and younger, and pregnant women over 24 who have risk factors (e.g., new sexual partner, unprotected sex, STI history).
  • Insufficient evidence to recommend screening in males.

Centers for Disease Control and Prevention (CDC)

  • All pregnant women
  • Annual testing for all sexually active women under age 26
  • Women 26 and older women with risk factors (new or multiple sex partners)
  • No routine testing for men, but consider screening men in high-prevalence settings (correctional facilities, STD clinics)

[tabby title=”Gonorrhea”]
American Congress of Obstetricians and Gynecologists (ACOG)

  • Annual Screening for sexually active females age 25 and younger
  • Screening for women over age 25 with risk factors (e.g., new/multiple partners)

U.S. Preventive Services Task Force (USPSTF)

  • All sexually active females, including those who are pregnant, if they have risk factors (similar to those with chlamydia)
  • Insufficient evidence to recommend routine screening for males

Centers for Disease Control and Prevention (CDC)

  • Pregnant women with risk factors (see chlamydia)
  • Wide screening is not recommended
  • argeted screening of women under age 26 at increased risk is prime component of gonorrhea control in the U.S.
  • Screen sexually active MSM annually for: urethral gonorrhea if insertive sex; rectal gonorrhea if receptive anal sex, pharyngeal gonorrhea if performed oral sex

[tabby title=”Syphilis”]
American Congress of Obstetricians and Gynecologists (ACOG)

  • Adolescents should be tested if risk factors are present

U.S. Preventive Services Task Force (USPSTF)

  • Persons at increased risk (MSM, commercial sex work, unprotected sex, those in correctional facilities)
  • All pregnant women
  • The Task Force makes no recommendation on routine screening of men and non-pregnant women not at increased risk for infection

Centers for Disease Control and Prevention (CDC)

  • All pregnant women
  • All sexually active MSM

[tabby title=”Genital Herpes”]
American Congress of Obstetricians and Gynecologists (ACOG)

  • No specific population guidelines

U.S. Preventive Services Task Force (USPSTF)

  • The Task Force does not recommend routine screening in asymptomatic adolescents and adults, including pregnant women.

Centers for Disease Control and Prevention (CDC)

  • Evidence does not support screening pregnant women for HSV-2

[tabby title=”Hepatitis B”]
American Congress of Obstetricians and Gynecologists (ACOG)

  • Pregnant women
  • Infants born to infected mothers
  • Sex partners of (and those living with) HBV+ persons
  • HIV+ persons
  • Injecting drug users
  • MSM
  • Healthcare workers with occupational exposure
  • Those treated with immunosuppressive drugs

U.S. Preventive Services Task Force (USPSTF)

  • Pregnant women at their first prenatal visit
  • The Task Force does not recommend routine screening for the asymptomatic general population

Centers for Disease Control and Prevention (CDC)

  • Routine screening of all pregnant women
  • Sexually-active MSM
  • Pre-vaccination screening an option for household, sexual, and needle-sharing contacts of HBV+ persons (to save costs of needless immunization)

[tabby title=”Hepatitis C”]
American Congress of Obstetricians and Gynecologists (ACOG)

  • HIV+
  • Injecting drug users
  • Those receiving clotting factors before 1987
  • Dialysis patients
  • Abnormal liver enzyme tests
  • Blood transfusion before 1992
  • Healthcare workers with occupational exposure

U.S. Preventive Services Task Force (USPSTF)

  • The Task Force does not recommend routine screening for the asymptomatic general population.
  • Insufficient evidence to recommend for or against routine screening for those with risk factors

Centers for Disease Control and Prevention (CDC)

  • All persons with HIV should be tested
  • Those with a history of injection drug use
  • Routine testing of MSM should be considered.

[tabby title=”HIV”]
American Congress of Obstetricians and Gynecologists (ACOG)

  • Women and men ages 19-64
  • Pregnant women and those in other age groups who have risk factors

U.S. Preventive Services Task Force (USPSTF)

  • All adolescents and adults at increased risk for infection (MSM, unprotected sex and multiple partners, commercial sex workers, injection drug users, blood transfusion between 1978 and 1985).
  • The Task Force makes no recommendation for screening those without risk factors.

Centers for Disease Control and Prevention (CDC)

  • HIV screening for patients ages 13-64 in all healthcare settings

[tabby title=”Pap Test”]
American Congress of Obstetricians and Gynecologists (ACOG)

  • Begin at age 21
  • Under 30, Pap every two years
  • 30 and over, Pap every three years with interval extended to three years following three consecutive, normal tests

U.S. Preventive Services Task Force (USPSTF)

  • Cytology in women ages 21-65 every three years
  • Centers for Disease Control and Prevention (CDC)
  • Summarized cervical cancer screening guidelines published by ACS, ACOG, and ASCCP

[tabby title=”HPV Test”]
American Congress of Obstetricians and Gynecologists (ACOG)

  • Women 30 and older may be tested with cytology alone or HPV/Pap co-testing

U.S. Preventive Services Task Force (USPSTF)

  • Women ages 30-65 who wish to extend screening intervals may use Pap/HPV co-test every five years

Centers for Disease Control and Prevention (CDC)

  • Triage for women 21 and older with ASC-US cytology. HPV/Pap co-testing in women 30+ years of age

[tabby title=”HPV Vaccines”]
American Congress of Obstetricians and Gynecologists (ACOG)

  • ACOG endorses ACIP recommendations for HPV vaccination in girls and young women: routine for ages 11-12 with catch-up for ages 13-26

U.S. Preventive Services Task Force (USPSTF)

  • No population-specific guidance

Centers for Disease Control and Prevention (CDC)

  • ACIP recommendations for HPV vaccination in girls and young women: routine for ages 11-12 with catch-up for ages 13-26. Routine use for males ages 11-12 with catch-up for ages 13-21.

[tabbyending]